{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:15:10Z","timestamp":1791976510824,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81560252"],"award-info":[{"award-number":["81560252"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Specialized fund for training of high-level talents in health and family planning in Yunnan Province of China","award":["201614"],"award-info":[{"award-number":["201614"]}]},{"name":"Specialized fund for training of high-level talents in health and family planning in Yunnan Province of China","award":["2017050"],"award-info":[{"award-number":["2017050"]}]},{"name":"Scientific Research Foundation of Yunnan Provincial Education Department of China","award":["2018JS209"],"award-info":[{"award-number":["2018JS209"]}]},{"name":"the Union Specific Foundation of Yunnan Province Technology Department and Kunming Medical University","award":["2018FE001(-310)"],"award-info":[{"award-number":["2018FE001(-310)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11096-019-00958-5","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T06:02:28Z","timestamp":1578463348000},"page":"23-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Effect of proton pump inhibitors on high-dose methotrexate elimination: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"42","author":[{"given":"Xi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6827-3441","authenticated-orcid":false,"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"key":"958_CR1","first-page":"293","volume":"2","author":"N Hagner","year":"2010","unstructured":"Hagner N, Joerger M. Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res. 2010;2:293\u2013301.","journal-title":"Cancer Manag Res"},{"issue":"12","key":"958_CR2","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471\u201382.","journal-title":"Oncologist"},{"issue":"6","key":"958_CR3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","volume":"11","author":"BC Widemann","year":"2006","unstructured":"Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694\u2013703.","journal-title":"Oncologist"},{"issue":"1","key":"958_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/BF00686028","volume":"33","author":"T Reid","year":"1993","unstructured":"Reid T, Yuen A, Catolico M, Carlson RW. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol. 1993;33(1):82\u20134.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"958_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2125.2005.02513.x","volume":"62","author":"M Joerger","year":"2006","unstructured":"Joerger M, Huitema AD, van den Bongard HJ, Baas P, Schornagel JH, Schellens JH, et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol. 2006;62(1):71\u201380.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"958_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1365-2125.2008.03303.x","volume":"67","author":"K Suzuki","year":"2009","unstructured":"Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009;67(1):44\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"7352","key":"958_CR7","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1136\/bmj.324.7352.1497","volume":"324","author":"U Troger","year":"2002","unstructured":"Troger U, Stotzel B, Martens-Lobenhoffer J, Gollnick H, Meyer FP. Drug points: severe myalgia from an interaction between treatments with pantoprazole and methotrexate. BMJ. 2002;324(7352):1497.","journal-title":"BMJ"},{"issue":"4","key":"958_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s11096-008-9204-9","volume":"30","author":"TG Bauters","year":"2008","unstructured":"Bauters TG, Verlooy J, Robays H, Laureys G. Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm World Sci. 2008;30(4):316\u20138.","journal-title":"Pharm World Sci"},{"issue":"9","key":"958_CR9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/bdd.2091","volume":"38","author":"K Narumi","year":"2017","unstructured":"Narumi K, Sato Y, Kobayashi M, Furugen A, Kasashi K, Yamada T, et al. Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: evaluation of drug-drug interactions mediated by organic anion transporter 3. Biopharm Drug Dispos. 2017;38(9):501\u20138.","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"958_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hon.2479","volume":"36","author":"F Ranchon","year":"2018","unstructured":"Ranchon F, Vantard N, Henin E, Bachy E, Sarkozy C, Karlin L, et al. Delayed methotrexate elimination: incidence, interaction with antacid drugs, and clinical consequences? Hematol Oncol. 2018;36(2):399\u2013406.","journal-title":"Hematol Oncol"},{"issue":"5","key":"958_CR11","first-page":"344","volume":"75","author":"E Boerrigter","year":"2017","unstructured":"Boerrigter E, Crul M. A non-interventional retrospective cohort study of the interaction between methotrexate and proton pump inhibitors or aspirin. Biopharm Drug Dispos. 2017;75(5):344\u20138.","journal-title":"Biopharm Drug Dispos"},{"key":"958_CR12","first-page":"1407","volume":"13","author":"T Tong","year":"2018","unstructured":"Tong T, Ni W, Wu Y, Tang L, Qu J, Zhang S. The correlation between delayed elimination of high dose methotrexate after treatment of malignant tumor when co-administered with proton pump inhibitors. Chin J Hosp Pharm. 2018;13:1407\u201310 (in Chinese language).","journal-title":"Chin J Hosp Pharm"},{"issue":"9","key":"958_CR13","first-page":"3807","volume":"30","author":"R Santucci","year":"2010","unstructured":"Santucci R, Leveque D, Lescoute A, Kemmel V, Herbrecht R. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res. 2010;30(9):3807\u201310.","journal-title":"Anticancer Res"},{"issue":"1","key":"958_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s002800050949","volume":"44","author":"J Whelan","year":"1999","unstructured":"Whelan J, Hoare D, Leonard P. Omeprazole does not alter plasma methotrexate clearance. Cancer Chemother Pharmacol. 1999;44(1):88\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"958_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/1078155213482602","volume":"20","author":"AJ Chan","year":"2014","unstructured":"Chan AJ, Rajakumar I. High-dose methotrexate in adult oncology patients: a case-control study assessing the risk association between drug interactions and methotrexate toxicity. J Oncol Pharm Pract. 2014;20(2):93\u20139.","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"958_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/bcp.12384","volume":"78","author":"DJ Reeves","year":"2014","unstructured":"Reeves DJ, Moore ES, Bascom D, Rensing B. Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors. Br J Clin Pharmacol. 2014;78(3):565\u201371.","journal-title":"Br J Clin Pharmacol"},{"key":"958_CR17","first-page":"1624","volume":"15","author":"Y Zou","year":"2018","unstructured":"Zou Y, Mei D, Fu Q, Du B, Duan M. Analysis of interaction drugs with high dose methotrexate in 1050 serum methotrexate concentration monitoring samples. Chin J Hosp Pharm. 2018;15:1624\u20138 (in Chinese language).","journal-title":"Chin J Hosp Pharm"},{"issue":"16","key":"958_CR18","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1158\/0008-5472.CAN-03-4062","volume":"64","author":"P Breedveld","year":"2004","unstructured":"Breedveld P, Zelcer N, Pluim D, S\u00f6nmezer O, Tibben MM, Beijnen JH, et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004;64(16):5804\u201311.","journal-title":"Cancer Res"},{"issue":"1","key":"958_CR19","first-page":"F122","volume":"276","author":"M Hosoyamada","year":"1999","unstructured":"Hosoyamada M, Sekine T, Kanai Y, Endou H. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol. 1999;276(1):F122\u20138.","journal-title":"Am J Physiol"},{"issue":"5","key":"958_CR20","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1124\/mol.59.5.1277","volume":"59","author":"SH Cha","year":"2001","unstructured":"Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001;59(5):1277\u201386.","journal-title":"Mol Pharmacol"},{"issue":"5","key":"958_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2133\/dmpk.19.369","volume":"19","author":"Y Uwai","year":"2004","unstructured":"Uwai Y, Taniguchi R, Motohashi H, Saito H, Okuda M, Inui K. Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004;19(5):369\u201374.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"12","key":"958_CR22","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1124\/dmd.114.058529","volume":"42","author":"R Chioukh","year":"2014","unstructured":"Chioukh R, Noel-Hudson MS, Ribes S, Fournier N, Becquemont L, Verstuyft C. Proton pump inhibitors inhibit methotrexate transport by renal basolateral organic anion transporter hOAT3. Drug Metab Dispos. 2014;42(12):2041\u20138.","journal-title":"Drug Metab Dispos"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-019-00958-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-019-00958-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-019-00958-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T01:22:39Z","timestamp":1609982559000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-019-00958-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["958"],"URL":"https:\/\/doi.org\/10.1007\/s11096-019-00958-5","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,8]]},"assertion":[{"value":"26 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author Xi Wang, Author Yanqin Song, Author Jingjing Wang, Author Jin He, Author Ruming Liu, Author Xiaosu Li, Author Hua Huang, Author Qin Yao, Author Jun Zhang, declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}